Stock Events

Stock Events

Vyne Therapeutics 

$41.52
54
-$0.97-2.28% Tuesday 19:59

Statistics

Day High
41.52
Day Low
41.52
52W High
46.15
52W Low
14.35
Volume
-
Avg. Volume
-
Mkt Cap
110.85M
P/E Ratio
-
Dividend Yield
47.31%
Dividend
19.64

Upcoming

Dividends

47.31%Dividend Yield
Jul 26
$0.38
Jul 26
$20.10
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

5NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-32.5
-21.71
-10.92
-0.13
Expected EPS
-16
Actual EPS
N/A

Financials

-4,646.14%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
570,000Revenue
-26.48MNet Income

Analyst Ratings

58.00Average Price Target
The highest estimate is 58.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VYNE. It's not an investment recommendation.
Apple
6
AAPL
Bionano Genomics
6
BNGO
NIO
5
NIO
Fuelcell Energy
5
FCEL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap224.63B
Amgen is a biotech company that develops treatments in areas similar to VYNE, including dermatology and inflammatory diseases.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie competes in the dermatology space with its portfolio of drugs, directly challenging VYNE's therapeutic areas.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson, through its pharmaceutical division Janssen, offers products that compete in the dermatological and autoimmune sectors against VYNE.
Pfizer
PFE
Mkt Cap152.69B
Pfizer has a broad range of products that include treatments for conditions VYNE targets, making them a direct competitor.
Merck
MRK
Mkt Cap335.14B
Merck operates in similar therapeutic areas as VYNE, including anti-inflammatory and dermatological conditions.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences focuses on inflammatory and respiratory diseases, competing with VYNE's product offerings.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals specializes in biopharmaceuticals for dermatology, directly competing with VYNE.
Novartis
NVS
Mkt Cap286.78B
Novartis offers products in dermatology and chronic diseases, areas where VYNE is also active.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol Myers Squibb has a diverse portfolio that includes treatments for immune-mediated diseases, competing with VYNE.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca has a focus on respiratory, cardiovascular, and autoimmune diseases, overlapping with VYNE's focus areas.

About

Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
Show more...
CEO
Rebecca Velez Frey
Employees
10
Country
United States
ISIN
US92941V2097

Listings

XNAS
US
VYNE
XNAS
US
YARW
BOATS
BOATS
VYNE.BOATS

0 Comments

Share your thoughts

FAQ

What is Vyne Therapeutics stock price today?▼
The current price of VYNE is $41.52 USD — it has decreased by -2.28% in the past 24 hours. Watch Vyne Therapeutics stock price performance more closely on the chart.
What is Vyne Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Vyne Therapeutics stocks are traded under the ticker VYNE.
Is Vyne Therapeutics stock price growing?▼
VYNE stock has risen by +23.61% compared to the previous week, the month change is a +9.12% rise, over the last year Vyne Therapeutics has showed a +149.37% increase.
What is Vyne Therapeutics market cap?▼
Today Vyne Therapeutics has the market capitalization of 110.85M
When is the next Vyne Therapeutics earnings date?▼
Vyne Therapeutics is going to release the next earnings report on November 05, 2026.
What were Vyne Therapeutics earnings last quarter?▼
VYNE earnings for the last quarter are -2.14 USD per share, whereas the estimation was -11 USD resulting in a +80.55% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Vyne Therapeutics revenue for the last year?▼
Vyne Therapeutics revenue for the last year amounts to 570,000 USD.
What is Vyne Therapeutics net income for the last year?▼
VYNE net income for the last year is -26.48M USD.
Does Vyne Therapeutics pay dividends?▼
Yes, VYNE dividends are paid en. The last dividend per share was 0.38 USD. As of today, Dividend Yield (FWD)% is 47.31%.
How many employees does Vyne Therapeutics have?▼
As of August 19, 2026, the company has 10 employees.
In which sector is Vyne Therapeutics located?▼
Vyne Therapeutics operates in the Health & Wellness sector.
When did Vyne Therapeutics complete a stock split?▼
The last stock split for Vyne Therapeutics was on February 13, 2023 with a ratio of 1:18.
Where is Vyne Therapeutics headquartered?▼
Vyne Therapeutics is headquartered in NEW HAVEN, United States.